GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Icure Pharmaceutical Inc (XKRX:175250) » Definitions » EV-to-FCF

Icure Pharmaceutical (XKRX:175250) EV-to-FCF : -9.09 (As of May. 29, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Icure Pharmaceutical EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Icure Pharmaceutical's Enterprise Value is ₩141,395 Mil. Icure Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-15,555 Mil. Therefore, Icure Pharmaceutical's EV-to-FCF for today is -9.09.

The historical rank and industry rank for Icure Pharmaceutical's EV-to-FCF or its related term are showing as below:

XKRX:175250' s EV-to-FCF Range Over the Past 10 Years
Min: -20.45   Med: -9.55   Max: -2.15
Current: -9.37

During the past 10 years, the highest EV-to-FCF of Icure Pharmaceutical was -2.15. The lowest was -20.45. And the median was -9.55.

XKRX:175250's EV-to-FCF is ranked worse than
100% of 528 companies
in the Drug Manufacturers industry
Industry Median: 23.61 vs XKRX:175250: -9.37

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-29), Icure Pharmaceutical's stock price is ₩1932.00. Icure Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-770.000. Therefore, Icure Pharmaceutical's PE Ratio for today is At Loss.


Icure Pharmaceutical EV-to-FCF Historical Data

The historical data trend for Icure Pharmaceutical's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icure Pharmaceutical EV-to-FCF Chart

Icure Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.85 -12.98 -11.91 -7.47 -9.12

Icure Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.88 -10.51 -8.07 -9.12 -9.39

Competitive Comparison of Icure Pharmaceutical's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Icure Pharmaceutical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Icure Pharmaceutical's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Icure Pharmaceutical's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Icure Pharmaceutical's EV-to-FCF falls into.



Icure Pharmaceutical EV-to-FCF Calculation

Icure Pharmaceutical's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=141395.013/-15554.919
=-9.09

Icure Pharmaceutical's current Enterprise Value is ₩141,395 Mil.
Icure Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-15,555 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Icure Pharmaceutical  (XKRX:175250) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Icure Pharmaceutical's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1932.00/-770.000
=At Loss

Icure Pharmaceutical's share price for today is ₩1932.00.
Icure Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-770.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Icure Pharmaceutical EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Icure Pharmaceutical's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Icure Pharmaceutical (XKRX:175250) Business Description

Traded in Other Exchanges
N/A
Address
7, Saimdang-ro 1-gil, Seocho-gu, Seoul, KOR
Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.

Icure Pharmaceutical (XKRX:175250) Headlines

No Headlines